Correlation between Nottingham Prognostic Index and Receptor status in breast cancer patients undergoing surgery

Not yet recruiting

• Conditions: Malignant neoplasm of breast of unspecified site, (2) ICD-10 Condition: C509||Malignant neoplasm of breast of unspecified site,

• Registration Number: CTRI/2025/04/085136
• Lead Sponsor: AIIMS, BBSR

Brief Summary

Breast cancer is one of the most common malignancies affecting women globally, accounting for a significant portion of cancer-related morbidity and mortality (1). Advances in early detection and treatment modalities have contributed to improved survival rates, yet the prognosis and outcomes remain highly variable among patients.

To stratify breast cancer patients and predict outcomes, various prognostic tools have been developed, among which the Nottingham Prognostic Index (NPI) is widely utilized (2) .The NPI incorporates three key variables: tumor size, lymph node involvement, and histological grade. It provides a quantitative framework to categorize patients into different prognostic grade, guiding therapeutic decision-making (3).

In recent years, there has been increasing interest in understanding the relationship between the NPI and receptor status in breast cancer patients. Hormone receptors, including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), play pivotal roles in tumor biology and are critical biomarkers for determining treatment strategies. ER and PR positivity typically indicate a more favorable prognosis and responsiveness to endocrine therapy, while HER2 positivity often correlates with more aggressive tumor behavior but is amenable to targeted therapies (4), (5).

The interplay between NPI and receptor status is of particular clinical significance. While the NPI provides a composite assessment of tumor burden and biological aggressiveness, receptor status reflects the underlying molecular characteristics of the tumor (6). Understanding the correlation between these two factors could enhance the accuracy of prognostication, enabling personalized treatment plans. For instance, patients with low NPI scores but HER2-positive tumors may require more intensive management than those with similar scores but hormone receptor-positive, HER2-negative profiles.

This study aims to explore the correlation between the NPI and receptor status in breast cancer patients undergoing surgery. By examining this relationship, we seek to provide insights into how the integration of NPI and receptor status can refine prognostic models and inform clinical decision-making.

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2025-04-18
• Study Start: 2025-04-29

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

• Carcinoma breast patients undergoing MRM 2.
• Carcinoma breast undergoing BCS+ALND.

Exclusion Criteria

Patients undergoing BCS+SLND.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Correlation between Nottingham prognostic index and receptor status in breast cancer undergoing surgery	4 weeks

Secondary Outcome Measures

Name	Time	Method
To evaluate the changes in hormonal receptor status after administration of NACT	8 weeks

Trial Locations

Locations (1)

All India Institute of Medical Science, Bhubaneswar; 🇮🇳 Khordha, ORISSA, India

All India Institute of Medical Science, Bhubaneswar

🇮🇳Khordha, ORISSA, India

Dr Varun SM

Principal investigator

7337842616

varungowdasm8@gmail.com